Ongoing Clinical Trials

 Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)

Purpose: The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.

ClinicalTrials.gov ID:

NCT00114777

Sponsor:

Bristol-Myers Squibb

Status:

Active, Not Enrolling


Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (Benefit)

Purpose: The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.

ClinicalTrials.gov ID:

NCT00256750

Sponsor:

Bristol-Myers Squibb

Status:

Active, Not Enrolling

 

Polyomavirus Aggregates, Haufen, in Voided Urine Samples as Diagnostic Biomarkers of Intra Renal BK-virus Disease: a Prospective Proof-of-concept Study

Purpose: To prospectively test whether the detection of three-dimensional, cast-like polyomavirus aggregates, termed Haufen, in voided urine samples can serve as an accurate biomarker of intra-renal disease, i.e. polyoma-BK-virus nephropathy (PVN). We want to correlate the detection of 'Haufen' with histologic findings made in renal biopsies as well as signs of polyomavirus activation, i.e. viremia and viruria. The prospective study is designed to further validate our retrospective findings (manuscript in press, J Am Soc Nephrol) and more specifically to correlate 'Haufen' shedding with the histologically confirmed course of PVN.

ClinicalTrials.gov ID:

NCT01094691

Sponsor:

University of North Carolina, Chapel Hill and Astellas Pharma, Inc.

Status:

Recruiting

 

Belatacept Conversion Trial in Renal Transplantation

Purpose: The purpose of this study is to learn if conversion to Belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied.

ClinicalTrials.gov ID: NCT00402168

Sponsor:

Bristol-Myers Squibb

Status:

Active, Not Enrolling